Prescription-Based Testing Segment to Dominate Europe Point of Care Diagnostics Market During 2021-2028
According to a new market research study on “Europe Point of Care Diagnostics Market to 2028 - COVID-19 Impact and Regional Analysis and Forecast by Product, Prescription Mode, and End-user” is expected to reach US$ 20,207.60 million by 2028 from US$ 8,948.81 million in 2021. The market is estimated to grow at a CAGR of 12.3% from 2021 to 2028. The report provides trends prevailing in the Europe point of care diagnostics market along with the drivers and restraints pertaining to the market growth. Escalating product launches and product developments and rising prevalence of infectious diseases are the major factor driving the growth of the Europe point of care diagnostics market. However, increasing product recalls in market hinders the growth of Europe point of care diagnostics market.
In case of COVID-19, Europe is highly affected specially France. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most affected European countries and number of deaths are also high. The current coronavirus (COVID-19) outbreak has been declared by WHO as a Public Health Emergency of International Concern, according to the International Health Regulation. Increasing number of coronavirus infections and demand for advanced diagnostic solutions is offering a favorable opportunity for adoption of point of care diagnostic kits in the region. Moreover, rising investments and business activities by industry players is also boosting the market even in pandemic situations. In 2020, European Medicines Agency (EMA) approved about 97 medicines for marketing authorization of which, 39 are novel drugs. Similarly, in October 2020, Eurofins introduces COVID-19 PCR tests with at-home self-sampling options in Europe region. Moreover, in October 2020, Siemens Healthineers launched rapid antigen test for diagnosis of COVID-19 in European countries. The CLINITEST rapid COVID-19 test is point of care cassette test that offers test result in 15 minutes. In addition, in April 2021, QIAGEN announced launch of Prep&Amp technology in order accelerate the COVID-19 diagnosis in Europe. The kit has received CE approval for marketing and distribution in Europe, also, the company has submitted its product for EUA (Emergency Use Application) in US. Such activities are likely to have constructive impact on market growth.
The Europe point of care diagnostics market has been segmented into the product, prescription mode, End-user, and country. Based on product, market has been segmented into the glucose monitoring products, infectious disease testing products, cardiometabolic testing products, pregnancy and fertility testing products, coagulation testing products, tumor/cancer marker testing products, cholesterol testing products, urinalysis testing products, hematology testing products, and other poc products. The glucose monitoring products segment dominated the market in 2020 and is expected to be fastest growing during forecast period. The infectious disease testing products segment has been further bifurcated into the HIV testing, influenza testing, sexually transmitted disease (STD) testing, hepatitis C testing, healthcare-associated infection (HAI) testing, tropical disease testing, respiratory infection testing, and other infectious disease testing. Based on prescription mode, market has been segmented into the prescription-based testing and OTC testing. The prescription-based testing segment dominated the market in 2020 and is also expected to be fastest growing during forecast period. Based on End-user, market has been segmented into the professional diagnostic centers, home care, research laboratories, and others. The professional diagnostic centers segment dominated the market in 2020 and home care segment is expected to be fastest growing during forecast period. The professional diagnostic centers is further segmented into the hospitals, clinical laboratories, outpatient healthcare, and ambulatory care settings.
Abbott; BD; bioMerieux SA; BIO-RAD LABORATORIES INC.; Danaher; F. HOFFMANN-LA ROCHE LTD.; Johnson and Johnson Services, Inc.; Nova Biomedical; Polymer Technology Systems, Inc. (PTS); and Siemens AG are among the leading companies in the Europe point of care diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Bio-Rad’s Multi-Target Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits Granted FDA Emergency Use Authorization.
In case of COVID-19, Europe is highly affected specially France. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most affected European countries and number of deaths are also high. The current coronavirus (COVID-19) outbreak has been declared by WHO as a Public Health Emergency of International Concern, according to the International Health Regulation. Increasing number of coronavirus infections and demand for advanced diagnostic solutions is offering a favorable opportunity for adoption of point of care diagnostic kits in the region. Moreover, rising investments and business activities by industry players is also boosting the market even in pandemic situations. In 2020, European Medicines Agency (EMA) approved about 97 medicines for marketing authorization of which, 39 are novel drugs. Similarly, in October 2020, Eurofins introduces COVID-19 PCR tests with at-home self-sampling options in Europe region. Moreover, in October 2020, Siemens Healthineers launched rapid antigen test for diagnosis of COVID-19 in European countries. The CLINITEST rapid COVID-19 test is point of care cassette test that offers test result in 15 minutes. In addition, in April 2021, QIAGEN announced launch of Prep&Amp technology in order accelerate the COVID-19 diagnosis in Europe. The kit has received CE approval for marketing and distribution in Europe, also, the company has submitted its product for EUA (Emergency Use Application) in US. Such activities are likely to have constructive impact on market growth.
The Europe point of care diagnostics market has been segmented into the product, prescription mode, End-user, and country. Based on product, market has been segmented into the glucose monitoring products, infectious disease testing products, cardiometabolic testing products, pregnancy and fertility testing products, coagulation testing products, tumor/cancer marker testing products, cholesterol testing products, urinalysis testing products, hematology testing products, and other poc products. The glucose monitoring products segment dominated the market in 2020 and is expected to be fastest growing during forecast period. The infectious disease testing products segment has been further bifurcated into the HIV testing, influenza testing, sexually transmitted disease (STD) testing, hepatitis C testing, healthcare-associated infection (HAI) testing, tropical disease testing, respiratory infection testing, and other infectious disease testing. Based on prescription mode, market has been segmented into the prescription-based testing and OTC testing. The prescription-based testing segment dominated the market in 2020 and is also expected to be fastest growing during forecast period. Based on End-user, market has been segmented into the professional diagnostic centers, home care, research laboratories, and others. The professional diagnostic centers segment dominated the market in 2020 and home care segment is expected to be fastest growing during forecast period. The professional diagnostic centers is further segmented into the hospitals, clinical laboratories, outpatient healthcare, and ambulatory care settings.
Abbott; BD; bioMerieux SA; BIO-RAD LABORATORIES INC.; Danaher; F. HOFFMANN-LA ROCHE LTD.; Johnson and Johnson Services, Inc.; Nova Biomedical; Polymer Technology Systems, Inc. (PTS); and Siemens AG are among the leading companies in the Europe point of care diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Bio-Rad’s Multi-Target Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits Granted FDA Emergency Use Authorization.
The report segments the Europe Point of Care Diagnostics Market as follows:
Europe Point of Care Diagnostics Market - By Product
- Glucose Monitoring Products
- Infectious Disease Testing Products
- HIV Testing
- Influenza Testing
- Sexually Transmitted Disease (STD) Testing
- Hepatitis C Testing
- Healthcare-Associated Infection (HAI) Testing
- Tropical Disease Testing
- Respiratory Infection Testing
- Other Infectious Disease Testing
- Cardiometabolic Testing Products
- Pregnancy and Fertility Testing Products
- Coagulation Testing Products
- Tumor/Cancer Marker Testing Products
- Cholesterol Testing Products
- Urinalysis Testing Products
- Hematology Testing Products
- Other POC Products
Europe Point of Care Diagnostics Market - By Prescription Mode
- Prescription-Based Testing
- OTC Testing
Europe Point of Care Diagnostics Market - By End-user
- Professional Diagnostic Centers
- Hospitals
- Clinical Laboratories
- Outpatient Healthcare
- Ambulatory Care Settings
- Home Care
- Research Laboratories
- Others
Europe Point of Care Diagnostics Market - By Country
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe point of care diagnostics market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in Europe point of care diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the point of care diagnostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Point of Care Diagnostics Market - Market Landscape
5. Europe Point of Care Diagnostics Market - Key Industry Dynamics
6. Point of Care Diagnostics Market - Europe Analysis
7. Europe Point of Care Diagnostics Market Analysis - by Product
8. Europe Point of Care Diagnostics Market Analysis - by Prescription Mode
9. Europe Point of Care Diagnostics Market Analysis - by End User
10. Europe Point of Care Diagnostics Market - Country Analysis
11. Impact of COVID-19 Pandemic on Europe Point of Care Diagnostics Market
12. Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- BD
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- Danaher
- F. Hoffmann-La Roche Ltd.
- Johnson and Johnson Services, Inc.
- Nova Biomedical
- Polymer Technology Systems, Inc. (PTS)
- Siemens AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | July 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 8948.81 Million |
| Forecasted Market Value ( USD | $ 20207.6 Million |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Europe |
